An opinion on the IP of EX1, page-10

Hi Davisite, really appreciate your input here. It appears that patent application first submitted in 2016 & now Exopharm are owners of that IP...so basically now we wait & leave it in the capabable hands of EX1 Management & Legal team. I totally understand what you are saying regarding timeframes for patents & others working around them. But it’s been some time...

I have to disagree with Biologics though, particularly MABs. This has been the new black in many treatments for a while now, very cutting edge, & many are still coming forth for new indications. Big Pharma can afford all the squabbles in courts. I think Exosomes will be the new Orange. Happy to be here! GLTA